Wednesday, August 8, 2012

Mylan Specialty and Pfizer Announce Licensing Agreement for EpiPen ® Injection 0.3/0.15mg in Japan

Under this Agreement, the exclusive marketing rights for the EpiPen ® injection in Japan, will be transferred to Pfizer Inc from Mylan Pharmaceutical Co., Ltd.. EpiPen ® injection  is currently marketed in Japan, the United States, Canada, South Africa, Australia, has been sold in several countries and Europe.

0.3mg and 0.15mg injection EpiPen ® is used as adjuvant therapy for anaphylactic reactions have been caused bee venom, food, drugs and the like. The target is limited to high-risk people to express or anaphylaxis, people with a history of anaphylaxis